ALBO - アルビレオ・ファ―マ (Albireo Pharma Inc.) アルビレオ・ファ―マ

 ALBOのチャート


 ALBOの企業情報

symbol ALBO
会社名 Albireo Pharma Inc (アルビレオ・ファ―マ)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アルビレオ・ファーマ(Albireo Pharma Inc.)(旧名:Biodel Inc.)は臨床段階の生物製薬会社である。同社は孤児小児肝疾患及び他の肝臓・胃腸の疾患と障害を治療するための胆汁酸モジュレーターの開発・商業化に従事する。臨床パイプラインは2つ以上の第II相製品候補と1つの第III相製品候補を含む。同社のパイプラインはA4250、A3384及びElobixibatを含む。A4250は進行性家族肝内胆汁うっ滞(PFIC)等の小児孤児胆汁うっ滞性肝疾患の治療方法として開発される。A3384は胆汁酸吸収不良(BAM)疾患を治療するために開発される。また、Elobixibatは慢性特発性便秘(CIC)を治療するために開発される。A4250とElobixibatは回腸胆汁酸トランスポーター(IBAT)の選択的阻害剤である。同社は19以上のBAM被験者を対象として、A3384のプロトタイプの第II相臨床試験を完了した。   アルビレオ・ファ―マは米国のバイオ医薬品メ―カ―。主に、糖尿病や骨粗しょう症などの内分泌障害 治療薬の開発と商品化に注力する。高分子量のインスリン吸収時間を速くする研究を行っており、超速効型インスリン「BIOD-123」や「BIOD531」を開発中。本社所在地はコネチカット州ダンバリ―。   Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.
本社所在地 10 Post Office Square Suite 502 South Boston MA 02109 USA
代表者氏名 David Chiswell デビッドチスウェル
代表者役職名 Independent Chairman of the Board
電話番号 +1 857-415-4774
設立年月日 37956
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 22人
url www.albireopharma.com
nasdaq_url https://www.nasdaq.com/symbol/albo
adr_tso
EBITDA EBITDA(百万ドル) -22.81400
終値(lastsale) 30.01
時価総額(marketcap) 359217539.28
時価総額 時価総額(百万ドル) 367.47680
売上高 売上高(百万ドル) 11.93100
企業価値(EV) 企業価値(EV)(百万ドル) 184.24880
当期純利益 当期純利益(百万ドル) -27.78900
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Albireo Pharma Inc revenues increased from $2K to $11.9M. Net loss increased 26% to $16.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects Research and development increase from $5.8M to $12.6M (expense) General and administrative increase from $3.7M to $8.4M (expense) Non-operating income (expense).

 ALBOのテクニカル分析


 ALBOのニュース

   Albireo Pharma, Inc. (NASDAQ:ALBO) Expected to Post Earnings of -$1.39 Per Share  2021/12/24 10:50:41 Dakota Financial News
Wall Street brokerages forecast that Albireo Pharma, Inc. (NASDAQ:ALBO) will post earnings of ($1.39) per share for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Albireo Pharmas earnings, with estimates ranging from ($2.11) to ($0.93). Albireo Pharma posted earnings per share of ($1.30) in the same quarter last year, []
   Albireo Pharma (NASDAQ:ALBO) Earns Buy Rating from Wedbush  2021/12/22 06:54:42 Transcript Daily
Wedbush reissued their buy rating on shares of Albireo Pharma (NASDAQ:ALBO) in a report released on Monday morning, PriceTargets.com reports. The brokerage currently has a $84.00 price target on the biopharmaceutical companys stock. A number of other equities analysts also recently commented on ALBO. Robert W. Baird restated a buy rating and issued a $72.00 []
   Chicago Capital LLC Boosts Stock Position in Albireo Pharma, Inc. (NASDAQ:ALBO)  2021/12/15 19:26:41 Transcript Daily
Chicago Capital LLC boosted its stake in shares of Albireo Pharma, Inc. (NASDAQ:ALBO) by 17.6% during the 3rd quarter, Holdings Channel.com reports. The firm owned 819,738 shares of the biopharmaceutical company’s stock after acquiring an additional 122,502 shares during the period. Chicago Capital LLC’s holdings in Albireo Pharma were worth $25,576,000 as of its most […]
   Albireo Announces Changes to R&D Organization  2021/12/09 14:00:00 Intrado Digital Media
BOSTON, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced the upcoming departure of Pat Horn, M.D., Ph.D., Chief Medical Officer, who will be leaving at the end of the year after almost three and a half years with the Company. Jan Mattsson, Ph.D., Chief Scientific Officer and co-founder of Albireo, will be taking over as the interim head of R&D, leading research and development of early and late-stage assets and programs. As one of the co-founders of the Company with deep experience in drug development and approvals, Dr. Mattsson is primed to lead the R&D organization with his institutional knowledge, vision for the pipeline and products, and ability to deliver against corporate objectives.
   Albireo Pharma, Inc. (NASDAQ:ALBO) Expected to Post Quarterly Sales of $5.08 Million  2021/12/06 18:02:42 Transcript Daily
Equities analysts forecast that Albireo Pharma, Inc. (NASDAQ:ALBO) will announce $5.08 million in sales for the current fiscal quarter, Zacks Investment Research reports. Five analysts have issued estimates for Albireo Pharmas earnings, with the lowest sales estimate coming in at $3.58 million and the highest estimate coming in at $5.88 million. Albireo Pharma reported sales []
   Albireo Pharma, Inc. (NASDAQ:ALBO) Expected to Post Earnings of -$1.39 Per Share  2021/12/24 10:50:41 Dakota Financial News
Wall Street brokerages forecast that Albireo Pharma, Inc. (NASDAQ:ALBO) will post earnings of ($1.39) per share for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Albireo Pharmas earnings, with estimates ranging from ($2.11) to ($0.93). Albireo Pharma posted earnings per share of ($1.30) in the same quarter last year, []
   Albireo Pharma (NASDAQ:ALBO) Earns Buy Rating from Wedbush  2021/12/22 06:54:42 Transcript Daily
Wedbush reissued their buy rating on shares of Albireo Pharma (NASDAQ:ALBO) in a report released on Monday morning, PriceTargets.com reports. The brokerage currently has a $84.00 price target on the biopharmaceutical companys stock. A number of other equities analysts also recently commented on ALBO. Robert W. Baird restated a buy rating and issued a $72.00 []
   Chicago Capital LLC Boosts Stock Position in Albireo Pharma, Inc. (NASDAQ:ALBO)  2021/12/15 19:26:41 Transcript Daily
Chicago Capital LLC boosted its stake in shares of Albireo Pharma, Inc. (NASDAQ:ALBO) by 17.6% during the 3rd quarter, Holdings Channel.com reports. The firm owned 819,738 shares of the biopharmaceutical company’s stock after acquiring an additional 122,502 shares during the period. Chicago Capital LLC’s holdings in Albireo Pharma were worth $25,576,000 as of its most […]
   Albireo Announces Changes to R&D Organization  2021/12/09 14:00:00 Intrado Digital Media
BOSTON, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare liver disease company developing novel bile acid modulators, today announced the upcoming departure of Pat Horn, M.D., Ph.D., Chief Medical Officer, who will be leaving at the end of the year after almost three and a half years with the Company. Jan Mattsson, Ph.D., Chief Scientific Officer and co-founder of Albireo, will be taking over as the interim head of R&D, leading research and development of early and late-stage assets and programs. As one of the co-founders of the Company with deep experience in drug development and approvals, Dr. Mattsson is primed to lead the R&D organization with his institutional knowledge, vision for the pipeline and products, and ability to deliver against corporate objectives.
   Albireo Pharma, Inc. (NASDAQ:ALBO) Expected to Post Quarterly Sales of $5.08 Million  2021/12/06 18:02:42 Transcript Daily
Equities analysts forecast that Albireo Pharma, Inc. (NASDAQ:ALBO) will announce $5.08 million in sales for the current fiscal quarter, Zacks Investment Research reports. Five analysts have issued estimates for Albireo Pharmas earnings, with the lowest sales estimate coming in at $3.58 million and the highest estimate coming in at $5.88 million. Albireo Pharma reported sales []

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アルビレオ・ファ―マ ALBO Albireo Pharma Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)